Madrigal Pharmaceuticals, Inc.
Clinical trials sponsored by Madrigal Pharmaceuticals, Inc., explained in plain language.
A biopharmaceutical company developing therapies for liver diseases, including NASH.
Not investment advice. Company information is shown for context only. Clinical trials frequently fail.
Advertising disclosure. Links marked "(ad)" go to partners we have a commercial relationship with, either a broker where you can trade or a stock-research service, and we may earn a commission if you open an account or subscribe. This never affects what is shown here.
Upcoming readouts
Trials from this sponsor expected to report results within the next 12 months.
- New drug aims to stop liver failure in NASH patients Results expected Dec 2026 (estimated) May already have reported ↗
- New pill shows promise for fatty liver in major trial Results expected Mar 2027 (estimated) May already have reported ↗
-
New pill could tame inherited high cholesterol
Disease control CompletedThis study tested an experimental drug called MGL-3196 (resmetirom) in 116 adults with heterozygous familial hypercholesterolemia, a genetic condition causing very high cholesterol. Participants took either the drug or a placebo daily for 12 weeks. The main goal was to see if the…
Phase 2 • Sponsor: Madrigal Pharmaceuticals, Inc. • Aim: Disease control
Last updated Jun 27, 2026 13:03 UTC
-
Promising new pill shrinks liver fat in NASH patients
Disease control CompletedThis phase 2 trial tested an oral drug called MGL-3196 in 125 adults with non-alcoholic steatohepatitis (NASH), a fatty liver disease that can lead to scarring and liver failure. The main goal was to see if the drug could reduce liver fat measured by MRI after 12 weeks compared t…
Phase 2 • Sponsor: Madrigal Pharmaceuticals, Inc. • Aim: Disease control
Last updated Jun 27, 2026 08:06 UTC
-
Kidney patients get closer to safer dosing of liver drug
Knowledge-focused CompletedThis completed Phase 1 study looked at how the drug resmetirom (Rezdiffra) is processed in the body of people with severe kidney impairment compared to healthy volunteers. 28 participants took a 100 mg pill once daily for 6 days. The goal was to measure drug levels and safety, no…
Phase 1 • Sponsor: Madrigal Pharmaceuticals, Inc. • Aim: Knowledge-focused
Last updated Jun 27, 2026 07:54 UTC